CFR Pharmaceuticals issued a firm intention announcement to acquire 100% of the issued share capital of Adcock Ingram. Read the full story

In M&A news, Simcere Pharmaceutical Group has entered into a merger agreement for around $495 million. Read the full story

In M&A news, Pharmstandard acquires Bever Pharmaceutical for $630 million after spinning out pharmaceutical business. Read the full story

Adcock Ingram received a non-binding bid from CFR Pharmaceuticals valuing Adcock Ingram at $1.3 billion according to dealtalk. Read the full story

OAO Pharmstandard, Russia’s biggest drugmaker, is considering the sale of an over-the-counter medicines business, according to pharma rumor mill sources. Read the full story

Zydus Cadila said it is looking for pharma partners to market its new chemical entity (NCE) Lipaglyn, to be used for treating a type of diabetes in developed and developing markets Read the full story

Ebos Group has agreed to buy Symbion, a pharmaceutical company, in a $1.1 billion M&A deal which will more than triple its annual revenues and make it a major player across Australasia. Read the full story

Tokai announced that the pharmaceutical company raised $35.5 million in a Series E financing based on encouraging clinical progress and investor support for galeterone, Tokai’s lead prostate cancer drug candidate. Read the full story

Auris Medical secures $50.6 Million in Series C financing deal. Read the full story

Rib-X Pharmaceuticals has closed the first tranche of a $67.5 million Series 2 preferred stock financing. Read the full story